Analysis of 104 Chinese Licensing-Out Deals Finds
Share of Multi-Asset Deals Rose from 32% to 43%
Big Pharma Focuses on Ability to Develop Follow-On Drugs

Editor's NoteAs China's industrial rise rapidly expands into new areas, its growing influence in the biotech sector is becoming increasingly pronounced. In particular, China has continuously achieved unprecedented or highly remarkable results in licensing deals for drug candidates with global big pharma companies over the past few years, readily outpacing competitors, including South Korea. This series examines where China's strength comes from and how South Korea, which once led China by building a reputation for reliability in the global industry, should respond going forward.

1. Big Pharma Sweeps Up China's New Drugs in Bulk

2. Hard to Sell Even Once, but China Sells Again and Again

3. China's Drug Sold for $8.4 Billion: Results Three Years Later

4. Can South Korea Withstand the Grueling Late-Stage Development Race?


Global big pharma companies' views of Chinese biotech have changed rapidly in recent years. Bold licensing deals that secure multiple drug candidates and drug discovery platforms at once have become much more common. Given the industry's precarious dealmaking practices, in which companies often terminate a deal and accept the loss of an upfront payment if even a minor issue arises after acquiring a single candidate at great effort, this suggests that Chinese biotech is now highly valued in the global market.

[China Shock, K-Industry on the Brink | Biotech] 1. Big Pharma Sweeps Up Chinese Drug Candidates in Bulk View original image

An analysis by The Asia Business Daily of relevant disclosures and announcements found that, among 104 deals worth at least $1 billion (approximately KRW 1.338 trillion) in which Chinese biotech companies licensed out assets to global big pharma companies over the past three years, the share of deals bundling two or more assets or programs, or including drug discovery platforms, rose from 31.8% in 2024 to 43.2% from January through September 2026. The share of potential deal value accounted for by these types of transactions increased from 46.6% to 68.6% over the same period. The proportion could rise further once fourth-quarter 2026 deals are included.


[China Shock, K-Industry on the Brink | Biotech] 1. Big Pharma Sweeps Up Chinese Drug Candidates in Bulk View original image

A deal between U.S.-based Bristol Myers Squibb (BMS) and China's Hengrui Pharmaceuticals is one example. In May 2026, BMS signed a licensing-in agreement with Hengrui Pharmaceuticals worth up to $15.2 billion (approximately KRW 20.3376 trillion). The deal covers 13 drug development programs, five of which do not yet have a designated drug candidate. In effect, BMS is betting on the possibility of discovering drug candidates together in the future.


China's share of the global technology licensing market has also grown. According to Boston Consulting Group (BCG), China-related deals accounted for 5% of global licensing deal value in 2019-2021, rising to 27% in 2022-2024. In 2025, they accounted for 48% as of December 1, exceeding the United States' 29%.


According to market research firm IQVIA, Chinese companies accounted for 40% of the assets originated by external companies and licensed in by global big pharma in 2025. That figure rose sharply in just one year, from less than 30% in 2024. The potential value of deals to license Chinese-developed therapies more than doubled, from $45 billion (approximately KRW 60.21 trillion) in 2024 to $105 billion (approximately KRW 14.49 trillion) in 2025, and reached $92 billion (approximately KRW 123.096 trillion) in the first half of 2026 alone.


In May 2026, Pfizer signed a deal with China's Innovent Biologics worth up to $10.5 billion (approximately KRW 14.049 trillion), securing 12 early-stage cancer drug candidates at once. Negotiations began at the J.P. Morgan Healthcare Conference in San Francisco in January 2026 and took less than five months.


After the deal, Innovent Biologics CEO Michael Yu said, "Pfizer preferred a single multi-asset deal from the outset." Rather than discovering, conducting due diligence on, and contracting for each of the 12 candidates separately, Pfizer secured multiple pipelines from one company in a single deal. Innovent Biologics will develop each candidate through Phase 1 clinical trials, after which Pfizer will lead global development. For some assets, the companies will share development costs in the United States and Europe and split sales profits.

[China Shock, K-Industry on the Brink | Biotech] 1. Big Pharma Sweeps Up Chinese Drug Candidates in Bulk View original image

The funds global pharmaceutical companies are investing in China are not limited to drug licensing deals. AstraZeneca plans to invest $15 billion (approximately KRW 20.07 trillion) in China by 2030 to expand its drug discovery, clinical development, and manufacturing capabilities. It will expand its research and development (R&D) centers in Beijing and Shanghai and invest in manufacturing facilities in Wuxi, Taizhou, Qingdao, and Beijing. Since 2023, the company has signed 16 global licensing deals with 15 Chinese companies. It is both acquiring promising drug candidates from external sources and expanding its local R&D base.



Global big pharma companies are also broadening their criteria for evaluating Chinese companies, moving beyond clinical data for individual candidates to include their ability to generate follow-on pipelines. The inclusion of not only existing candidates but also programs to be discovered in the future in licensing deals reflects this shift. An industry insider in South Korea said, "When a company believes that one firm can continue to produce good candidates, demand emerges to secure its discovery system and follow-on pipeline early, rather than signing deals for individual assets alone."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing